HIV疫苗蓝图

The infection of rhesus macaques with a chimeric virus uncovers a recipe for broadly neutralizing antibodies James Binley The impact of therapies against HIV is limited by their cost, clinical infrastructure requirements, and patient adherence. An effective vaccine could be a more cost-effective and practical solution to control the spread of HIV. One approach to develop such a vaccine is to stimulate B cells of the immune system to produce broadly neutralizing antibodies (bnAbs) against the virus. However, the diversity of the HIV envelope glycoprotein (Env) makes it difficult to generate bnAbs that can recognize all viral variants. The shield of glycans (sugars) that forms the external surface of Env masks potential bnAb targets and exacerbates the problem. …